Nanocan Therapeutics Corporation is a Princeton, New Jersey based early stage biotechnology company developing cutting-edge, nanotechnology based innovations for therapeutic medicines to treat certain cancers where current interventions are insufficient. The Company’s inventions deploy smart radiotherapy biomaterials (nanoparticle drones), as a drug-delivery platform. Nanocan’s nanoparticle drones can be employed to sustainably deliver different drug payloads – including immunotherapy drugs, chemotherapy drugs, and phytomedicines – precisely to disease sites or targets, with greater therapeutic efficacy. Through its partnerships with leading academic research institutions, Nanocan is rapidly developing therapies that may ultimately result in new standards of care to help improve the lives of cancer patients. Nanocan is committed to making its disruptive innovations available to cancer patients in the U.S. and globally, including Low and Middle-Income Countries (“LMICs”), starting with countries in Africa.